Revolution Medicines (RVMD) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 9/21/2026 – Revolution Medicines had its price target raised by Bank of America Corporation from $225.00 to $265.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Revolution Medicines is now covered by Morgan Stanley. They set an “overweight” rating and a $255.00 price target on the stock.
• 9/9/2026 – Revolution Medicines had its price target raised by Stifel Nicolaus from $215.00 to $230.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by UBS Group AG from $220.00 to $265.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by Guggenheim from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $203.00 to $251.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $248.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Oppenheimer Holdings, Inc. from $230.00 to $260.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $320.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by HC Wainwright from $195.00 to $280.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Wedbush from $201.00 to $225.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $231.00 to $239.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Revolution Medicines was upgraded by TD Cowen to “strong-buy”.
• 8/21/2026 – Revolution Medicines had its price target raised by Sanford C. Bernstein from $151.00 to $179.00. They now have a “market perform” rating on the stock.
• 8/11/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $210.00 to $231.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wolfe Research. They now have a $220.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Wedbush from $192.10 to $201.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $182.00 to $203.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Guggenheim from $235.00 to $240.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $236.00 to $240.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Revolution Medicines had its price target raised by Wedbush from $181.00 to $192.10. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Revolution Medicines

In related news, insider Mark Goldsmith sold 13,988 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the sale, the insider owned 253,342 shares in the company, valued at $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan Sandler sold 341 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $67,940.84. Following the transaction, the insider directly owned 52,868 shares of the company’s stock, valued at $10,533,420.32. This trade represents a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 300,119 shares of company stock worth $60,605,043. 7.60% of the stock is owned by company insiders.

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.